Compare FUL & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FUL | LIVN |
|---|---|---|
| Founded | 1887 | 1987 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.5B |
| IPO Year | N/A | 1993 |
| Metric | FUL | LIVN |
|---|---|---|
| Price | $60.52 | $63.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | ★ $68.50 | $62.43 |
| AVG Volume (30 Days) | 381.6K | ★ 602.4K |
| Earning Date | 01-14-2026 | 11-05-2025 |
| Dividend Yield | ★ 1.56% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.07 | N/A |
| Revenue | ★ $3,502,085,000.00 | $1,348,962,000.00 |
| Revenue This Year | N/A | $12.25 |
| Revenue Next Year | $2.02 | $6.75 |
| P/E Ratio | $29.24 | ★ N/A |
| Revenue Growth | N/A | ★ 8.63 |
| 52 Week Low | $47.56 | $32.48 |
| 52 Week High | $74.64 | $65.57 |
| Indicator | FUL | LIVN |
|---|---|---|
| Relative Strength Index (RSI) | 61.45 | 62.94 |
| Support Level | $57.48 | $61.81 |
| Resistance Level | $61.47 | $65.57 |
| Average True Range (ATR) | 1.24 | 1.74 |
| MACD | 0.35 | -0.10 |
| Stochastic Oscillator | 78.80 | 56.21 |
H.B. Fuller Co manufactures and sells adhesives, sealants, and other chemical-based products. The company organizes itself into three segments: Hygiene, Health and Consumable Adhesives, Engineering Adhesives and Construction Adhesives. It generates the maximum revenue from hygiene, health and consumable adhesives. This segment produces and supplies a full range of specialty industrial adhesives such as thermoplastic, thermoset, reactive, water-based and solvent-based products for applications in various markets, including packaging , converting, nonwoven and hygiene (disposable diapers, feminine care and medical garments) and health and beauty. The company generates around half of its revenue in the United States.
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.